FRANKFURT, Germany, March 8 /PRNewswire/ -- t2cure, a biopharmaceutical company engaged in the field of stem cell-based regenerative medicine, announced today that it has appointed Dr. Manfred Ruediger as CEO.
“Dr. Ruediger is an executive with a strong scientific background who has gained a broad spectrum of experience and knowledge in various functions within the biotech industry. This experience and knowledge is now available to t2cure. We are happy having recruited such an experienced and well connected CEO for our company. Dr. Ruediger will further grow t2cure, will establish the necessary structures of a biopharmaceutical company and carve out the strategy of t2cure”, says Prof. Andreas M. Zeiher, co-founder of t2cure.
“I am fascinated by this new challenge, where I can shape a start-up company that is built on a mature pipeline and phase II clinical data. My goal is to establish t2cure as a leading company in the field of regenerative therapies for cardiovascular disease and - together with the two founders and our investors - to develop new treatment options for patients up to the market,” says Dr. Manfred Ruediger, CEO.
Dr. Ruediger received his PhD in biochemistry from the University of Tuebingen, Germany and worked at the Max Planck Institute for Biophysical Chemistry and at the Technical University of Braunschweig before he joined the industry. He has more than 8 years of experience in the international biotech industry, where he served in various executive positions. He was CSO and acting CEO of Cardion AG (Germany), CEO of Igeneon AG (Vienna, Austria) and most recently COO of NASDAQ-listed Aphton Corporation (Philadelphia, USA). In these positions he was responsible for various in- and out-licensing activities, as well as M&A activities. Specifically, licensing agreements with Roche, Pfizer, Celltrion and Protein Design Labs and the acquisition of Igeneon AG by Aphton were done under his responsibility. Currently, he serves on the Board of Directors of public 4SC AG and also served on the Boards of G2M AG and of Vectron Therapeutics AG.
Contact t2cure GmbH Bettinastrasse 35-37 D-60325 Frankfurt am Main Tel: +49-69-75-61-46-87-0 Fax: +49-69-75-61-46-87-9 Email: info@t2cure.com www.t2cure.com
About t2cure GmbH t2cure GmbH is a biopharmaceutical company engaged in the field of stem cell-based regenerative medicine. It develops autologous bone marrow-derived progenitor cells as regenerative therapeutics for cardiovascular disease including ischemic heart disease (acute myocardial infarction and chronic ischemic heart disease, non-ischemic heart failure, peripheral arterial occlusive disease, and diabetic polyneuropathy. The most advanced project (t2c001-AMI) has successfully passed phase II of clinical development and is now prepared to enter phase III. t2cure is privately financed with Entrepreneurs Fund BV, Amsterdam as lead investor.
Source: t2cure GmbH
